Morgan Stanley downgraded Alphatec from Overweight to Equal-Weight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/28/2025 | $20.00 | Buy | Stifel |
| 10/24/2025 | $19.00 | Overweight | Analyst |
| 6/16/2025 | $18.00 | Buy | Lake Street |
| 8/1/2024 | Overweight → Equal-Weight | Morgan Stanley | |
| 7/8/2024 | $19.00 | Overweight | Barclays |
| 2/9/2024 | $26.00 | Overweight | Wells Fargo |
| 12/19/2023 | $16.00 → $18.00 | Buy | Needham |
| 10/20/2023 | $22.00 | Buy | ROTH MKM |
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
ATEC Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic Alignment Theradaptive Initiates Series B to Advance Proprietary Protein-Engineering Technology CARLSBAD, Calif. and FREDERICK, Md., Jan. 12, 2026 /PRNewswire/ -- Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing spine surgery, and Theradaptive, Inc., a clinical-stage regenerative medicine company pioneering engineered protein therapeutics, today announced a definitive strategic partnership agreement. Concurrently, Theradaptive announced the initiation of a Series B investment round designed to accelerate the expansion of its proprietary protein-engineering platf
Full-year 2025 total revenue grew 25% to approximately $764 million Expect full-year 2026 total revenue of $890 million Alphatec Holdings, Inc. (NASDAQ:ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary financial results for the fourth quarter and full-year ended December 31, 2025. The Company also provided a financial outlook for full-year 2026. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Select Financial Results Fourth Quarter Ended December 31, 2025 Full Year Ended December 31, 2025 Surgical Revenue $189.3M to $190.0M $686.3M to
Alphatec Holdings, Inc. (NASDAQ:ATEC) ("ATEC"), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced with great sadness that Jeffrey P. Rydin, a valued member of its Board of Directors, has passed away at age 59, following a lengthy illness. Mr. Rydin enjoyed nearly three decades of experience in the medical device and healthcare industries, including senior sales leadership roles at Ellipse Technologies, Inc., NuVasive, Inc., and DePuy Spine, Inc. He was one of the earliest to join the ATEC turnaround effort, coming to the Company as a Special Advisor to the Board in September 2016, in which capacity he drove many of the early deci
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
Stifel resumed coverage of Alphatec with a rating of Buy and set a new price target of $20.00
Analyst initiated coverage of Alphatec with a rating of Overweight and set a new price target of $19.00
Lake Street resumed coverage of Alphatec with a rating of Buy and set a new price target of $18.00
8-K - Alphatec Holdings, Inc. (0001350653) (Filer)
144 - Alphatec Holdings, Inc. (0001350653) (Subject)
8-K - Alphatec Holdings, Inc. (0001350653) (Filer)
Alphatec Holdings, Inc. (NASDAQ:ATEC) ("ATEC"), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced with great sadness that Jeffrey P. Rydin, a valued member of its Board of Directors, has passed away at age 59, following a lengthy illness. Mr. Rydin enjoyed nearly three decades of experience in the medical device and healthcare industries, including senior sales leadership roles at Ellipse Technologies, Inc., NuVasive, Inc., and DePuy Spine, Inc. He was one of the earliest to join the ATEC turnaround effort, coming to the Company as a Special Advisor to the Board in September 2016, in which capacity he drove many of the early deci
Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi
Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri
Full-year 2025 total revenue grew 25% to approximately $764 million Expect full-year 2026 total revenue of $890 million Alphatec Holdings, Inc. (NASDAQ:ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary financial results for the fourth quarter and full-year ended December 31, 2025. The Company also provided a financial outlook for full-year 2026. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Select Financial Results Fourth Quarter Ended December 31, 2025 Full Year Ended December 31, 2025 Surgical Revenue $189.3M to $190.0M $686.3M to
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2025 financial results on October 30, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations section of ATEC's corporate website. Dial-In To dial into the live webcast, please register at this link. Access details will be provided via email. Replay A replay of the webcast will remain available through the Investor Relations section of ATEC's corporate website for twelve month
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2025 financial results on July 31, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months.
SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)
SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)
SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)